RLMD – relmada therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
Form SCHEDULE 13G/A RELMADA THERAPEUTICS, Filed by: Squadron Capital Management LLC
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Spruce Street Capital LP
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Adage Capital Management, L.P.
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: JANUS HENDERSON GROUP PLC
Form 424B5 RELMADA THERAPEUTICS,
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.